The Serine/Threonine Protein Kinase ATR pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase ATR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase ATR pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Infectious Disease which include the indications Solid Tumor, Ovarian Cancer, Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS). It also reviews key players involved in Serine/Threonine Protein Kinase ATR targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase ATR pipeline targets constitutes close to 25 molecules. Out of which, approximately 24 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 10, 2, 1, 7, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Serine/Threonine Protein Kinase ATR overview
Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1.
For a complete picture of Serine/Threonine Protein Kinase ATR’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
